PRINCETON, NJ – 2019年7月9日 – Certara has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve equity in health for all people worldwide.
This webinar described some important strategic considerations for successful development of complex biologics including appropriate data collection and timings, analyses requiring cross-functional data integration, and key pharmacology-related critical questions.
PRINCETON, NJ – Oct. 24, 2018 – Certara today announced that Craig Rayner, PharmD, MBA, senior vice president, integrated drug development with Certara Strategic Consulting, has been awarded the 2018 Distinguished Alumni Award for the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University.
Clinical pharmacology gap analysis is a tool for outlining your drug program’s needs, prioritizing these needs, and providing a framework for how to satisfy them. This tool can create value for drug development programs. While gap analysis can be performed at any point in the drug development continuum, early engagement is best for maximizing its benefits. … Continued
In this webinar, Pau Aceves, Associate Director of Consulting Services at Certara, presented case studies on how tracer kinetics were used to inform development of new drugs for lung, CNS, and liver diseases. By watching this webinar, you will learn how tracer kinetics can leveraged for PK, PD, and in silico modeling applications.
Changing the Game, Optimizing Success, Increasing Value: Committed to scientific and regulatory advancement, Certara has integrated its capabilities to create impactful healthcare solutions.
PRINCETON, NJ – 2018年6月14日 – Certara was privileged to participate as a key member of the Medicines Development for Global Health development team to achieve FDA approval of moxidectin.
This webinar introduced the importance of bioanalysis and its downstream effects on clinical development and clinical pharmacology.
There are numerous challenges in developing oncology drugs: (1) they are often very toxic which precludes conducting clinical trials in healthy volunteers, (2) the PK of a drug may be altered in cancer patients due to demographic and physiological differences as compared to healthy volunteers, and (3) cancer patients face elevated drug-drug interaction (DDI) risk … Continued
